Ridong Chen
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$16.6MFederal grants as PI23 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
23 awards · $16.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Mar 26, 2025 | NIH | SBIR Phase II Multi-functional anti-thrombotic therapy for coronary microvascular obstruction | $1.7M | APT THERAPEUTICS, INC. |
| Apr 19, 2024 | NIH | SBIR Phase II Multi-functional anti-thrombotic therapy for coronary microvascular obstruction | $1.4M | APT THERAPEUTICS, INC. |
| Jul 14, 2023 | NIH | SBIR Phase II Immunomodulatory Therapy for Neuropathic Pain | $501K | APT THERAPEUTICS, INC. |
| May 1, 2023 | NIH | SBIR Phase II Multi-functional anti-thrombotic therapy for coronary microvascular obstruction | $1.6M | APT THERAPEUTICS, INC. |
| Aug 15, 2022 | NIH | SBIR Phase II Immunomodulatory Therapy for Neuropathic Pain | $922K | APT THERAPEUTICS, INC. |
| Sep 17, 2021 | NIH | SBIR Phase II Immunomodulatory Therapy for Neuropathic Pain | $996K | APT THERAPEUTICS, INC. |
| Jun 4, 2021 | NIH | SBIR Phase I Peripherally Acting Analgesic for Osteoarthritis Pain | $260K | APT THERAPEUTICS, INC. |
| Sep 15, 2020 | NIH | SBIR Phase I Anti-inflammatory and Anti-diabetic Therapy for Metabolic Syndrome | $300K | APT THERAPEUTICS, INC. |
| Sep 18, 2019 | NIH | SBIR Phase I Synergistic Efficacy of an Interleukin 2 Analog and Antitumor Antigen Antibody | $300K | APT THERAPEUTICS, INC. |
| Sep 16, 2019 | NIH | SBIR Phase I Combination treatment with tPA and IL2 analog for Stroke | $345K | APT THERAPEUTICS, INC. |
| Apr 12, 2019 | NIH | SBIR Phase II Antithrombotic Therapy with No Bleeding Risk for PCI | $724K | APT THERAPEUTICS, INC. |
| Sep 1, 2018 | NIH | SBIR Phase I Prevention of Post-MI Heart Failure with Immunomodulatory Therapy | $338K | APT THERAPEUTICS, INC. |
| Aug 23, 2018 | NIH | SBIR Phase I Immunomodulatory Therapy for Neuropathic Pain | $299K | APT THERAPEUTICS, INC. |
| Apr 16, 2018 | NIH | SBIR Phase I Synergistic Anti-tumor Efficacy of an Interleukin 2 Analog and PD-1 blockade | $300K | APT THERAPEUTICS, INC. |
| Sep 15, 2017 | NIH | SBIR Phase I Immunomodulatory Therapy for Diabetic Nephropathy | $279K | APT THERAPEUTICS, INC. |
| Apr 19, 2017 | NIH | SBIR Phase II Antithrombotic Therapy with No Bleeding Risk for PCI | $300K | APT THERAPEUTICS, INC. |
| Apr 18, 2017 | NIH | SBIR Phase II Antithrombotic Therapy with No Bleeding Risk for PCI | $1.9M | APT THERAPEUTICS, INC. |
| Sep 14, 2016 | NIH | SBIR Phase I IL2-based Immunotherapy for Lupus | $225K | APT THERAPEUTICS, INC. |
| Aug 1, 2016 | NIH | SBIR Phase I Human Apyrase Therapy for Acute Ischemic Stroke | $2.7M | APT THERAPEUTICS, INC. |
| Apr 29, 2016 | NIH | SBIR Phase I IL2-based Immunotherapy for Type 2 Diabetes | $299K | APT THERAPEUTICS, INC. |
| Sep 18, 2015 | NIH | SBIR Phase I Optimized IL2-based Therapy for Type 1 Diabetes | $298K | APT THERAPEUTICS, INC. |
| Sep 1, 2015 | NIH | SBIR Phase I Low-dose IL-2-based Immunomodulatory Therapy for PAH | $297K | APT THERAPEUTICS, INC. |
| Jul 16, 2015 | NIH | SBIR Phase I Human Apyrase Therapy for Diabetic Neuropathic Pain | $300K | APT THERAPEUTICS, INC. |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#12
Awards as PI#12
Patents#273
Companies
- APT THERAPEUTICS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.